What is the appropriate treatment for vaginal candidiasis?

Treatment of Vaginal Candidiasis

For uncomplicated vaginal candidiasis, either topical azole antifungals or a single 150-mg oral dose of fluconazole are equally effective first-line treatments, with the choice depending primarily on patient preference and cost considerations. 1

Classification and Initial Approach

Vaginal candidiasis is classified into uncomplicated (90% of cases) and complicated (10% of cases) based on severity, recurrence pattern, causative species, and host factors. 1

Confirm the Diagnosis Before Treatment

• Perform wet-mount microscopy with 10% KOH to visualize yeast forms, pseudohyphae, or true hyphae, and confirm vaginal pH of 4.0–4.5. 1, 2
• Obtain fungal culture with species identification and antifungal susceptibility testing when microscopy is negative but clinical suspicion remains high, or when symptoms recur despite treatment—this identifies non-albicans species and azole resistance. 1, 2
• Avoid empirical antifungal therapy without laboratory confirmation in more than 55% of cases to prevent unnecessary medication exposure and resistance development. 2

---

Treatment of Uncomplicated Vulvovaginal Candidiasis

First-Line Options (Equally Effective)

• Topical intravaginal azole antifungals for 1–7 days (no single agent is superior to another)—strong recommendation with high-quality evidence. 1
• Oral fluconazole 150 mg as a single dose—strong recommendation with high-quality evidence. 1

Both routes achieve equivalent clinical cure rates exceeding 90%, with oral therapy probably improving mycological cure slightly at short-term (80–85% vs. 80%) and long-term follow-up (67–76% vs. 66%). 3

Choosing Between Oral and Topical Therapy

• Oral fluconazole is generally preferred by patients for convenience, though the evidence certainty is low. 3
• Topical agents cause more local irritation (burning, itching at application site), while oral fluconazole causes more systemic side effects (gastrointestinal symptoms, headaches). 3
• Withdrawal rates due to adverse effects are low and similar for both routes—high-certainty evidence. 3
• Cost should be considered: if patients are self-paying, provide full information about characteristics and costs of both options to allow informed choice. 3

---

Treatment of Severe Acute Vulvovaginal Candidiasis

Fluconazole 150 mg every 72 hours for 2–3 total doses (not a single dose)—strong recommendation with high-quality evidence. 1, 2

• Single-dose fluconazole is explicitly inadequate for severe disease and should be avoided. 2

---

Treatment of Recurrent Vulvovaginal Candidiasis (≥4 Episodes/Year)

Induction Phase

10–14 days of induction therapy using either:

• Topical azole antifungal, OR
• Oral fluconazole 150 mg every 72 hours for 2–3 doses 1, 2

Maintenance Phase

Fluconazole 150 mg once weekly for 6 months—strong recommendation with high-quality evidence. 1, 2

• Approximately 50% of women with one VVC episode will have at least one recurrence, and 10% develop recurrent VVC (≥4 episodes/year) according to CDC guidelines. 2
• Probiotics may have a role in reducing recurrence, with some evidence showing negative correlation between probiotic consumption and recurrence rate, though this is not yet a guideline recommendation. 4

---

Treatment of Non-Albicans Candidiasis (Especially C. glabrata)

Non-albicans species account for 10–20% of VVC cases and often exhibit azole resistance, requiring alternative therapy. 2

First-Line for Azole-Unresponsive C. glabrata

Intravaginal boric acid 600 mg (in gelatin capsule) once daily for 14 days—strong recommendation with low-quality evidence. 1, 2

Alternative Regimens

• Nystatin intravaginal suppositories 100,000 units daily for 14 days—strong recommendation with low-quality evidence. 1, 2
• Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream daily for 14 days—weak recommendation with low-quality evidence. 1

---

Common Pitfalls and Caveats

• PCR detection of Candida does not confirm active infection: up to 20% of asymptomatic women are colonized with Candida, creating risk of false-positive results. 2
• Thick white discharge with vulvar burning is classic for VVC, but symptoms are nonspecific and overlap with bacterial vaginosis, trichomoniasis, desquamative inflammatory vaginitis, and cytolytic vaginosis—always confirm with pH and microscopy. 1, 2
• Vulvar involvement (edema, erythema, excoriation, fissures) occurs because Candida directly invades vulvar tissue as it spreads from the vaginal canal. 2
• If symptoms persist despite appropriate treatment, reconsider the diagnosis: evaluate for desquamative inflammatory vaginitis, genitourinary syndrome of menopause, or vulvodynia. 5
• Emerging therapies such as oteseconazole and ibrexafungerp show promise for recurrent or resistant cases, though they are not yet widely incorporated into guidelines. 6, 7